Skip to main content

Table 4 Changes of plasma myeloperoxidase levels

From: Impact of hemodialysis solutions containing different levels of molecular hydrogen (H2) on the patient-reported outcome of fatigue

 

All

Group A

Group B

Group C

p value (among groups)

Pre-HD: MPO pg/mL

Baseline

73.3 ± 54.1

94 1 ± 93.9

73.5 ± 44.6

67.5 ± 42.4

0.22

8th week

72.0 + 63.1

93.7 ± 105.3

77.0 ±  76.4

63.5 ± 33.2

0.21

p value

0.79

0.98

0.75

0.98

 

Post-HD: MPO pg/mL

Baseline

283.5 ± 215.2

370.6 ± 293.3

229.9  ± 165.8

287.2 ± 208.3

0.10

8th week

271.8 ± 221.0

317.1 ± 222.4

195.0 ± 54.9

299.1 ±  242.1

0.07

p value

0.47

0.51

0.002

0.53

 

Pre-HD: LN(MPO pg/mL)

Baseline

4.11 ± 0.58

4.26 ± 0.69

4.12 ±  0.61

4.06 ± 0.53

0.46

8th week

4.07 ± 0.58

4.17 ± 0.76

4.08 ± 0.67

4.03 ± 0.47

0.68

p value

0.39

0.54

0.67

0.54

 

Post-HD: LN(MPO pg/mL)

Baseline

5.41 ± 0.70

5.66 ± 0.73

5.18 ± 0.76

5.46 ± 0.64

0.06

8th week

5.32 ± 0.77

5.55 ± 0.64

4.98 ± 0.78

5.43 ± 0.74

0.01

p value

0.02

0.52

0.002

0.52

 
  1. MPO, myeloperoxidase; LN, natural logarithm
  2. Group A (n = 16): patients who reported fatigue on both HD and HD-free days at baseline; Group B (n = 30): patients who reported fatigue on HD days, but not on HD-free days; Group C (n = 59): patients who did not report fatigue on both HD and HD-free days